Milestone Scientific reaffirms 2026 revenue outlook of $9.8 mln to $10.2 mln
Company expects CompuFlo revenue to grow faster than overall business in 2026
Company says Q3 revenue may be lower due to seasonality and fewer large international orders
Overview
Medical device maker's Q2 revenue rose 22% yr/yr, driven by dental and medical segment growth
Medical segment revenue grew 231% yr/yr, reflecting increased CompuFlo adoption and reimbursement progress
Net loss narrowed to $1.1 mln from $1.5 mln a year ago
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$2.80 mln
$2.70 mln (2 Analysts)
Q2 Loss Per Share
$0.01
Q2 Net Loss
$1.10 mln
Q2 Gross Profit
$1.90 mln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Milestone Scientific Inc is $1.00, about 80.8% above its August 13 closing price of $0.55
MLSS•
